Abstract
Sulodexide decreases the formation of thrombi and it supports the natural fybrinolytic activity of the body. By affecting the level of fibrinogen and due to its antiplatelet acting it also decrease blood viscosity and it improves the perfusion of some tissues.
The administration of sulodexide in the prevention of thromboembolitic events in patients with higher risk (obese patients, elderly patients, immobilization, varicose veins, tumors, metabolic disorders or chronic venous disorders) or in patients with a history of such diaseses is signoficant. First of all, sulodexide comes in useful in those patients who are from various reasons ineligible for full heparinization or oral anticoagulation, or possibly in such patients who are not appropriate for such procedures.
Sulodexide provides the benefit of an oral administration and in standard dosing there is no need to monitor coagulation parameters. The paper presents the experience with sulodexide treatment in two female patients with chronic venous insufficiency and with a history of venous thrombosis after the withdrawal of warfarin respectively.